pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Small Molecule · news · pharmadog
← back to Small Molecule
News · Small Molecule
466
stories
25d
Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
fiercebiotech
25d
Disc sets up polycythemia vera challenge but Silence maintains lead
biospace
25d
FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer
fiercebiotech
26d
In first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacy
fiercebiotech
26d
Tyra shares slip as bladder cancer responses fall short of investor expectations
biospace
26d
11 companies hiring in California now
biospace
27d
Tyra disappoints investors with bladder cancer data
biopharma dive
27d
STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea
stat
27d
Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
biospace
27d
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
fiercebiotech
27d
FDA solidifies CDER, CBER leadership posts as commissioner confirmation awaits
fiercebiotech
27d
Evommune's MRGPRX2 antagonist flunks its second I&I trial this summer
endpoints
27d
Beeline flies into phase 3 as oral lupus drug soars past placebo
fiercebiotech
28d
Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy
biopharma dive
28d
Pharvaris' stock jumps on pivotal success in rare genetic disease
endpoints
28d
Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics
fiercebiotech
28d
Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data drop
biospace
28d
Novo shutters 2 more heart disease studies, indicating IL-6 is ‘invalid target’
biospace
28d
AstraZeneca’s SERD pill overcomes adcomm defeat to win FDA nod in breast cancer
biospace
28d
FDA approves AstraZeneca’s Etcamah, opening ctDNA-guided treatment paradigm in breast cancer
fiercebiotech
28d
Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pending
fiercebiotech
28d
AI will only revolutionize drug discovery and development if we play to its strengths
biospace
29d
FDA approves AstraZeneca’s oral SERD for breast cancer despite negative adcomm vote
endpoints
Sep 4, 26
FDA Grants Accelerated Approval to a New Breast Cancer Treatment
fda press
Sep 3, 26
An AI drug specialist zeroes in on rare forms of obesity
biopharma dive
Sep 3, 26
Chutes & Ladders—Invivyd's chairman adds CEO role ahead of COVID readout
fiercebiotech
Sep 3, 26
The pediatricians who take in vaccine-skeptical parents others won’t
stat
Sep 2, 26
Beyond GLP‑1s: The race for next‑gen obesity drugs starts in the preclinical models
biospace
Sep 2, 26
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
Sep 1, 26
Alumis’ TYK2 drug fails in key lupus study
biopharma dive
← prev
page 4 of 16
next →
